Nature Reviews Cardiology - Table of Contents alert Volume 12 Issue 9

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
September 2015 Volume 12 Number 9
Impact Factor 9.183 *	In this issue Research Highlights News and Views Reviews Also this month  Web collection: Noncoding RNAs in cardiovascular disease
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Anticoagulation therapy: Benefits of extended oral anticoagulation after first episode of pulmonary embolism Published online: 28 July 2015 p499 | doi:10.1038/nrcardio.2015.118 PDF Prevention: Guidelines with high statin eligibility target risk and are cost-effective Published online: 04 August 2015 p500 | doi:10.1038/nrcardio.2015.119 PDF Aortic disease: Endovascular vs open AAA repair Published online: 11 August 2015 p500 | doi:10.1038/nrcardio.2015.122 PDF Device therapy: Defibrillation testing unnecessary during routine cardioverter-defibrillator implantation Published online: 14 July 2015 p501 | doi:10.1038/nrcardio.2015.111 PDF Risk factors: Long-term low mortality in patients without coronary artery calcium Published online: 04 August 2015 p501 | doi:10.1038/nrcardio.2015.120 PDF Cardiology EVENT 3rd Annual International Conference on Cardiology and Cardiovascular Medicine Research (CCMR 2016) 22.02.16 Singapore More science events from
NEWS AND VIEWS		Top
Regulatory science: Trust and transparency in clinical trials of medical devices Daniel B. Kramer & Donald E. Cutlip Published online: 21 July 2015 p503 | doi:10.1038/nrcardio.2015.112 Regulatory approval of high-risk cardiovascular devices is on the basis of clinical studies submitted with a premarket approval application. Failure to publish many of these studies in peer-reviewed literature, and major discrepancies between premarket approval submissions and those studies that are published, raise important questions for clinicians and other stakeholders. Full Text | PDF
Device therapy: Saving lives with appropriate ICD therapy in elderly patients Valentina Kutyifa & Arthur J. Moss Published online: 28 July 2015 p504 | doi:10.1038/nrcardio.2015.114 Sudden cardiac death in elderly patients with recent myocardial infarction and reduced left ventricular ejection fraction can be substantially reduced using implantable cardioverter-defibrillators (ICDs) in appropriately selected, high-risk cardiac patients. Increased use of ICD therapy among eligible elderly patients will save lives. Full Text | PDF
REVIEWS		Top
Contributions of risk factors and medical care to cardiovascular mortality trends Majid Ezzati, Ziad Obermeyer, Ioanna Tzoulaki, Bongani M. Mayosi, Paul Elliott & David A. Leon Published online: 16 June 2015 p508 | doi:10.1038/nrcardio.2015.82 Cardiovascular disease (CVD) remains a leading cause of death worldwide, but age-standardized CVD death rates are decreasing steadily. In this Review, Ezzati and colleagues use the available epidemiological data to examine regional and global changes in CVD mortality, as well as trends in smoking, alcohol consumption, diet, physiological risk factors, and improvements in medical care that might underlie these changes. Abstract | Full Text | PDF | Supplementary information
Gene therapy to treat cardiac arrhythmias Rossana Bongianino & Silvia G. Priori Published online: 28 April 2015 p531 | doi:10.1038/nrcardio.2015.61 Gene therapy for cardiac arrhythmias is now undergoing clinical testing. In this Review, Bongianino and Priori discuss the principles of gene therapy and how this approach can be tailored and targeted to the heart. They then summarize the preclinical and clinical experience of gene therapy applied to acquired and inherited arrhythmias of the atria or ventricles. Abstract | Full Text | PDF
Cardiotoxicity of anticancer treatments Michael S. Ewer & Steven M. Ewer Published online: 12 May 2015 p547 | doi:10.1038/nrcardio.2015.65 Patients with cancer often experience concomitant cardiovascular disease that results from the malignant process itself, or from anticancer treatment. Treatment-induced cardiotoxicity can be either transient or irreversible, and is associated with arrhythmia, ischaemia, and myocardial infarction. The authors discuss the mechanisms by which anticancer treatments damage the heart, and suggest potential strategies on how to protect patients with cancer from anticancer therapy-induced cardiotoxicity. Abstract | Full Text | PDF
Advertisement
Primers in your inbox Nature Reviews Disease Primers launched in April 2015 and publishes Primers — introductory review articles that provide overviews of diseases and disorders. Primer articles describe all aspects of a condition: epidemiology; disease mechanisms; diagnosis, screening and prevention; management; and quality of life.  Stay updated on the latest Primers published.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Cardiology was previously published as Nature Clinical Practice Cardiovascular Medicine.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.